Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (436)	1/3/2004 2:06:08 PM
From: scaram(o)uche	Respond to of 625

Baxter and Abbott.... veteran biotech investors would LOVE to see them get what's coming. Put me on a jury, please.

To: keokalani'nui who wrote (436)	1/3/2004 4:27:06 PM
From: nigel bates	Respond to of 625

I'm sure it will be more than just the royalties. As Garland said just before leaving... "The announcement of this dispute with Abbott coincided with our plan to merge with Oxford GlycoSciences, which was ultimately unsuccessful.” Still, it will be neither quick, nor cheap. If I get the chance, I'll try to watch some of the proceedings. ....CAT’s lawyers, Herbert Smith, expected the dispute to come to court in the next 12 to 18 months. Legal costs are estimated at £2 million to £3 million a year.